Amgen Share News

"The Dow® [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to numerous investors

Amgen has maintained an impressive dividend streak over the past decade. The company's business should allow it to maintain this momentum for a while.

24/7 Wall St. Insights Jefferies is one of Wall Street's fastest-growing firms.

Amgen has been one of the best performing stocks since its IPO in 1983. Over the prior 12 months, the biotech's shares have continued this rich tradition.

The drugmaker has a promising weight-loss drug in clinical trials, MariTide, which could be a game changer. Recent acquisitions have bolstered Amgen's portfolio, which could pave the way for even more growth.

Biotech stocks operate under a core ethos. While there's been much talk about financially viable sectors – from tech to cryptocurrencies to even precious metals – when you think about it, nothing is more valuable than one's health.

Amgen continues to delight investors with the growth in sales of its key blockbusters and the expansion of its portfolio of medications. In mid-June, Amgen pleased investors by announcing that the FDA had approved Blincyto to treat certain patients with B-precursor acute lymphoblastic leukemia. Ten days earlier, the company released promising results from a Phase 3 clinical trial evaluating Upl...

Dow Jones stocks to watch in the stock market this week.